Dehydrated Human Amnion/Chorion Membrane as Adjunctive Therapy in the Multidisciplinary Treatment of Pyoderma Gangrenosum: A Case Report.

Pyoderma gangrenosum (PG) is an uncommon chronic and progressive skin disorder that can lead to severe tissue necrosis, pathergy, horrendous pain, and disfigurement if not properly and promptly diagnosed and treated. Systemic treatment traditionally consists of long-term immunosuppression. Topical care of the painful wound often represents a clinical challenge. A 77-year-old woman with multiple comorbidities including venous insufficiency and diabetes mellitus was diagnosed through exclusion with refractory, painful PG. She was managed for 3 months by a multidisciplinary team comprised of an internist, 2 dermatologists, and a podiatric wound care specialist using immunosuppressive therapy, several local wound care modalities, and supportive bandages. During that time, severe wound pain continued unabated and the affected area changed from 3 separate wounds measuring 1.4 cm x 1.0 cm x .01 cm, 1.2 cm x 0.5 cm x 0.1 cm, and 0.6 cm x 0.5 cm x 0.1 cm to 1 wound measuring 8.0 cm x 10.3 cm x 0.1 cm. At that time, dehydrated human amnion/chorion membrane (dHACM) allograft, previously reported to facilitate healing venous leg and diabetic foot ulcers, was incorporated into the treatment plan. The patient reported wound pain decreased from 10 out of 10 to 5 out of 10 within hours following application. At the 4 day follow-up visit, she reported no pain; after 1 week, the wound decreased 6.4 cm x 9.4 cm x 0.1 cm in size and after 2 months (3 applications) the wound had reduced in area from 103 cm2 to 57.96 cm2 (reduced by more than half [56%]). In this patient, following the application of dHACM as an adjunct to immunosuppressive therapy, pain receded and wound healing commenced. Additional controlled studies are needed to ascertain the generalizability of this observation.

[1]  T. Koob,et al.  Cytokines in single layer amnion allografts compared to multilayer amnion/chorion allografts for wound healing. , 2015, Journal of biomedical materials research. Part B, Applied biomaterials.

[2]  R. Snyder,et al.  The use of human amnion/chorion membrane in the clinical setting for lower extremity repair: a review. , 2015, Clinics in podiatric medicine and surgery.

[3]  Marissa J Carter,et al.  A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers , 2014, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[4]  T. Koob,et al.  Angiogenic properties of dehydrated human amnion/chorion allografts: therapeutic potential for soft tissue repair and regeneration , 2014, Vascular cell.

[5]  R. Kelly,et al.  Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent. , 2013, Journal of the American Academy of Dermatology.

[6]  T. Serena,et al.  A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers , 2013, International wound journal.

[7]  R. Snyder,et al.  Scientific and clinical support for the use of dehydrated amniotic membrane in wound management. , 2012, Wounds : a compendium of clinical research and practice.

[8]  R. Kirsner,et al.  Dynamic reciprocity in the wound microenvironment , 2011, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[9]  Robert J Snyder,et al.  Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. , 2010, Ostomy/wound management.

[10]  E. Ruocco,et al.  Pyoderma gangrenosum: an updated review , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  P. Blume,et al.  Comparison of Negative Pressure Wound Therapy Using Vacuum-Assisted Closure With Advanced Moist Wound Therapy in the Treatment of Diabetic Foot Ulcers , 2008, Diabetes Care.

[12]  G. Dunnill,et al.  Diagnosis and treatment of pyoderma gangrenosum , 2006, BMJ : British Medical Journal.

[13]  A. Heiligenhaus,et al.  Transplantation of amniotic membrane in murine herpes stromal keratitis modulates matrix metalloproteinases in the cornea. , 2005, Investigative ophthalmology & visual science.

[14]  Thomas John,et al.  Human amniotic membrane transplantation: past, present, and future. , 2003, Ophthalmology clinics of North America.

[15]  P. R. Dahl,et al.  Skin ulcers misdiagnosed as pyoderma gangrenosum. , 2002, The New England journal of medicine.

[16]  D. H. Ma,et al.  Identification of Antiangiogenic and Antiinflammatory Proteins in Human Amniotic Membrane , 2000, Cornea.

[17]  A. Fleischer,et al.  Pyoderma Gangrenosum A Comparison of Typical and Atypical Forms with an Emphasis on Time to Remission. Case Review of 86 Patients from 2 Institutions , 2000, Medicine.

[18]  R. Snyder,et al.  Cadaveric allograft as adjunct therapy for nonhealing ulcers. , 1999, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.

[19]  S. Burge,et al.  Lesson of the week: Early diagnosis of pyoderma gangrenosum is important to prevent disfigurement , 1998, BMJ.

[20]  J. Gruss,et al.  Human amniotic membrane: a versatile wound dressing. , 1978, Canadian Medical Association journal.

[21]  J. Pigeon Treatment of second-degree burns with amniotic membranes. , 1960, Canadian Medical Association journal.